<DOC>
	<DOCNO>NCT01164228</DOCNO>
	<brief_summary>RATIONALE : Sunitinib malate may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , gemcitabine hydrochloride , work different way stop growth tumor cell , either kill cell stop dividing . It yet know whether give sunitinib malate gemcitabine hydrochloride together effective sunitinib malate alone treat patient kidney cancer . PURPOSE : This randomized phase II clinical trial study give sunitinib malate together without gemcitabine hydrochloride see well work treat patient advanced kidney cancer remove surgery .</brief_summary>
	<brief_title>Sunitinib Malate With Without Gemcitabine Hydrochloride Treating Patients With Advanced Kidney Cancer That Can Be Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate response rate sunitinib malate v without gemcitabine hydrochloride patient advance renal cell carcinoma sarcomatoid feature . Secondary - To evaluate progression-free survival patient . - To evaluate overall survival patient . - To describe toxic effect sunitinib malate alone combination gemcitabine hydrochloride patient . OUTLINE : This multicenter study . Patients stratify accord risk ( good risk [ clear cell &lt; 20 % sarcomatoid performance status ( PS ) 0 ] v intermediate risk [ 20-50 % sarcomatoid PS 0 ] v poor risk [ non-clear cell &gt; 50 % sarcomatoid PS 1 non-clear cell ] ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive gemcitabine hydrochloride IV 30 minute day 1 , 8 , 22 , 29 oral sunitinib malate daily day 1-14 22-35 . - Arm II : Patients receive oral sunitinib malate daily day 1-14 22-35 . In arm , course repeat every 42 day 1 year absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year every 6 month 1 year . PROJECTED ACCRUAL : A total 100 patient ( 60 arm I 40 arm II ) accrue study .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirmed* renal cell carcinoma Disease subtype allow Disease must sarcomatoid feature NOTE : *Patients must paraffinembedded tumor specimen kidney metastatic site available central review confirmation tumor histology No collect duct medullary carcinoma Measurable advance disease resectable surgery Patients resect radiated brain metastasis treat stereotactic radiation therapy eligible , provided steroid least 2 week PATIENT CHARACTERISTICS : ECOG performance status 02 AGC ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 9.0 g/dL ( transfusion allow ) Serum creatinine clearance ≥ 30 mL/min SGOT SGPT ≤ 2.5 time ULN ( ≤ 5 time ULN presence liver metastasis ) Total bilirubin ≤ 1.5 time ULN Baseline QTc interval &lt; 500 msec EKG Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception study treatment Able swallow pills No history stroke within past 6 month No clinically significant cardiovascular disease , define one following : Uncontrolled hypertension ( BP &gt; 150/100 mm Hg time enrollment ) Patients hypertension BP ≤ 150/100 mm Hg stable antihypertensive regimen eligible History myocardial infarction unstable angina within past 24 week NYHA class IIIV congestive heart failure , serious cardiac arrhythmia require medication , unstable angina pectoris Peripheral vascular disease ≥ grade II No ongoing ventricular cardiac dysrhythmias ≥ grade 2 assessed NCI CTCAE version 4 No patient history serious ventricular arrhythmia ( ventricular tachycardia ventricular fibrillation &gt; 3 beat row ) No patient ongoing atrial fibrillation No preexisting thyroid abnormality thyroidstimulating hormone maintain less within normal range medication No serious concurrent illness active infection would jeopardize ability patient receive study treatment No known HIV Patients history prior malignancy eligible provide treated curative intent disease free time period consider appropriate interfere outcome study PRIOR CONCURRENT THERAPY : No prior systemic therapy metastatic disease Patients randomize placebo adjuvant study eligible More 2 week since prior radiotherapy recover Previously irradiate lesion must sole site disease More 2 week since prior concurrent ketoconazole , dexamethasone , dysrhythmic drug ( terfenadine , quinidine , procainamide , sotalol , probucol , bepridil , indapamide , flecainide ) , haloperidol , risperidone , rifampin , grapefruit , grapefruit juice Topical inhale steroid allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>recurrent renal cell cancer</keyword>
	<keyword>stage IV renal cell cancer</keyword>
	<keyword>clear cell renal cell carcinoma</keyword>
	<keyword>papillary renal cell carcinoma</keyword>
	<keyword>clear cell sarcoma kidney</keyword>
</DOC>